Clinical Ink is a global life science company that brings data, technology, and patient science together. Clinical Ink’s platform is powered by deep therapeutic-area expertise, coupled with Direct Data Capture (DDC), electronic clinical outcome assessment (eCOA), eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, ushering in a new generation of clinical trials. By harnessing digital data, the company enables sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.
Investment Details
Initial Investment Date: August 2020
GI Role: Lead Investor
Status: Current
